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Measurement of baseline locomotion and other behavioral 
traits in a common marmoset model of Parkinson's disease 
established by a single administration regimen of 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data 
for efficacious preclinical evaluations
Kiyoshi Andoa, Takashi Inouea, Keigo Hikishimaa,b, Yuji Komakia,  
Kenji Kawaia, Ryo Inouea, Chiyoko Nishimea, Eiko Nishinakaa,  
Koji Uranoa and Hideyuki Okanoc,d   
Baseline locomotion and behavioral traits in the common 
marmoset Parkinson's disease model were examined 
to provide basic information for preclinical evaluations 
of medical treatments. A single regimen of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine at a cumulative dose 
of 5 mg/kg as the free base over three consecutive days 
was administered subcutaneously to 10 marmosets. 
Data obtained from these marmosets were compared 
to pre-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
levels or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
free marmosets. After the single regimen, reduced daily 
locomotion, a measure of immobility (a primary sign of 
Parkinsonism), was observed for more than a year. A 
moving tremor was also observed by visual inspection 
during this period. When apomorphine (0.13 mg/kg, s.c.) 
was administered, either right or left circling behavior was 
observed in a cylindrical chamber in 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine marmosets, suggestive of unequal 
neural damage between the two brain hemispheres to 
different extents. MRI revealed that T1 relaxation time in 
the right substantia nigra correlated with right circling in 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets. 
Histology was supportive of dopaminergic neural loss in 
the striatum. These results increase our understanding 
of the utility and limitations of the Parkinson's disease 
model in marmosets with a single 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine regimen, and provide reference 
data for efficacious preclinical evaluations. Behavioural 
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Introduction
Parkinson's disease (PD) is a progressive neurodegenerative 
disorder characterized by movement impairments such as 
immobility, tremor, muscle rigidity, and positional dysfunc-
tion. Underlying degeneration is evident in the dopaminergic 
neurons originating from the substantia nigra and extend-
ing to the striatum (Olanow and Tatton, 1999). Movement 
impairments are mainly associated with degeneration of the 
nigrostriatal dopaminergic neural system, which in the nor-
mal brain plays a key role in smooth movement function.
Although movement impairments are typically the pri-
mary topic of PD studies, many other central nervous 
system-related manifestations and disorders have been 
reported, such as cognitive impairment, hallucinations, 
delusions, depression, irritability, sleep disorders, and 
olfactory dysfunction (Löhle et al., 2009). Autonomic 
nervous system-related disorders have also been reported, 
such as orthostatic hypotension, constipation, early sati-
ety, excessive sweating, and urinary urgency (Khoo et al., 
2013). These manifestations of PD are considered indic-
ative of the broad linkage not only from the nigrostriatal 
dopaminergic system to the cortex via the thalamus but 
also from noradrenergic, serotonergic, cholinergic, and 
other neural systems (Masilamoni and Smith, 2018). 
These manifestations may derive from the pathophysi-
ology of PD, or from complications of other neurological 
disorders, such as Alzheimer's disease and dementia with 
Lewy bodies, in addition to PD medication.
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Although, it remains unclear whether the above manifesta-
tions are directly related to the pathophysiology of PD, some 
of them have been explored using laboratory animal models. 
Further investigations of disease manifestations, such as cog-
nitive dysfunction, may be required and have been already 
reported in preclinical PD studies (Phillips et al., 2017).
A neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP), has been used to establish PD models in var-
ious primate species (Langston et al., 1984a; Langston et al., 
1984b). In MPTP-treated primates, the neural damage and 
syndrome is similar to that of human PD patients (Tetrud 
and Langston, 1989). Thus, primates model have been 
used to study the pathophysiology, etiology, and pathogen-
esis of PD, and to evaluate potential medical treatments in 
the preclinical stage (Fox and Brotchie, 2010).
The common marmoset is a nonhuman primate with a 
body size comparable to that of a large adult rat. MPTP-
treated marmosets show a similar behavioral syndrome 
and dopaminergic neural degeneration to PD patients, 
and thus have been used in preclinical studies (Jenner, 
2003). Marmosets are easy to handle, compared to 
macaque monkeys, and show relatively few individual 
differences in behavioral traits and toxicological sensitiv-
ity to MPTP (Ando, 2004). The relative behavioral homo-
geneity of the marmoset as an experimental primate is 
considered attributable to the raising of this nonhuman 
primate species basically under a random non-inbred sys-
tem in a controlled in-house closed colony over the past 
30 years in Japan.
In terms of behavioral traits at baseline, a normal mar-
moset living in its individual living cage moves freely, 
leaps between mesh cage walls, clings to the wall in the 
daytime, and remains still at night (Ando et al., 2012). 
Infrared motion sensor measurements of daily contin-
uous locomotion of an individual normal caged marmo-
set remain stable across days and months. Following 
MPTP administration, a decreased level of locomotion 
is observed for several weeks or more. A stable level 
of decreased locomotion after MPTP is considered an 
objective and quantitative measure of immobility, which 
is a primary syndrome of Parkinsonism. In addition, 
locomotion provides a sensitive baseline for evaluating 
the beneficial effects of drugs (Ando et al., 2008) and 
other medical treatments such as deep brain stimulation 
and neural tissue/cell transplantation. Although, the 
MPTP-induced decrease in locomotion is an important 
measure, this level recovers spontaneously after MPTP 
treatment (with some individual variability). This can 
be avoided if extensive damage is induced by a higher 
dose MPTP regimen, in which case marmosets show 
severe manifestations leading to death. The protective 
effects against MPTP toxicity of a preclinical treatment 
have also been shown, supporting that the marmoset 
PD model should use a single regimen of MPTP rather 
than multiple regimens (Ando et al., 2008).
Multiple regimens of MPTP may complicate the exper-
imental process. Therefore, characterization of behavio-
ral stability after a single, optimal regimen of MPTP is 
important to understand the utility and limitations of this 
approach in preclinical studies.
In this report, we investigated baseline locomotion 
behavior over a period of several months in marmosets 
that received a single regimen of MPTP in experiment 
1. Other PD-like signs were observed in the same exper-
iment using a dysfunction scale. The following experi-
ments were performed by using the same marmosets 
that received the above MPTP regimen. In experiment 
2, influences (direct and indirect effects) of MPTP on 
food-reinforced choice behavior were investigated with 
the expectation of detecting cognitive behavioral impair-
ment. In experiment 3, long-lasting but latent influ-
ences of MPTP were explored by observing the circling 
behavior induced by subcutaneous (s.c.) administration 
of apomorphine (a dopamine receptor agonist), which is 
suggestive of imbalanced nigrostriatal neural damage in 
the two brain hemispheres. In experiment 4, in-vivo MRI 
was performed to detect signal changes in the brain after 
the MPTP regimen compared to the pre-MPTP condi-
tion. In experiment 5, neural degeneration was grossly 
and macroscopically confirmed in marmosets received the 
present MPTP regimen by in-vitro immunohistochemi-




This study was conducted in strict accordance with rec-
ommendations of the Guide for the Care and Use of 
Laboratory Animals published by the National Research 
Council (USA). The study protocol was reviewed by 
the CIEA animal care and use committee and approved 
by our institute (CIEA; approval no. 07028A). The cri-
teria used by the committee complied with those man-
dated by the Japanese Law for the Humane Treatment 
and Management of Animals. This study was designed 
and conducted under the principle of the three Rs 
(Replacement, Reduction, and Refinement).
Animals and husbandry
Healthy adult male common marmosets were obtained 
from CLEA Japan, Inc. (Tokyo, Japan). Their body 
weight and age were in the range of 339–481 g and 2.8–
4.1 years, respectively, at the time of animal selection. 
Lists of the marmosets used in the present experiments 
are provided in Table 1, including sample sizes and iden-
tification codes. During the experimental period, each 
marmoset was housed in an individual stainless-steel 
cage (50 cm high, 30 cm wide, and 48 cm deep) with wire-
mesh walls and floor. Animals were administered 50 g/day 
of a balanced diet (CMS-1M; CLEA Japan, Inc.) and free 
access to tap water from feed valves. The colony room 
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was illuminated from 09:00 to 21:00 hours. The temper-






MPTP hydrochloride powder (Lot: 067K1946; Sigma-
Aldrich Co., St. Louis, Missouri, USA) was dissolved in 
physiological saline at a concentration of 1 mg/ml. MPTP 
doses were calculated and expressed as the free base 
excluding the weight of hydrochloride. The weight of 
the MPTP free base was 1.21 times the weight of MPTP 
hydrochloride.
Single regimen of 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
We focused on a single regimen of MPTP to investigate 
behavioral changes over more than 1 year. Our ration-
ale for using a single MPTP regimen is described in the 
Introduction. The MPTP was s.c. to 10 drug-naive mar-
mosets on three consecutive days (free base doses of 2, 2, 
and 1 mg/kg on days 0, 1, and 2, respectively). Thus, the 
total cumulative dose of MPTP was 5 mg/kg over three 
consecutive days. During the 3 days of MPTP adminis-
tration and the subsequent 2-week period, supplements 
(orally administered nutrient solution and s.c.-adminis-
tered electrolyte solution) were administered to mar-
mosets, as described previously (Ando et al., 2012), to 
compensate for the anorexia and dehydration caused by 
MPTP toxicity. The present regimen was selected on the 
basis of our unpublished pilot study, in which MPTP reg-
imens (free base doses of 2, 1, and 1 mg.kg s.c. for group 
A, and of 2, 2, and 1 mg/kg s.c. for group B, on days 0, 1 
and 2, respectively) were tested using three marmosets in 
each group. The single regimen of MPTP (2, 2, and 1 mg/
kg, s.c. on three consecutive days) was used in the pres-
ent study because marmosets for the group B showed 
clear manifestations without weakening or death, at least 
during the 1-month period in which preclinical evalua-
tion tests were performed.
Experiment 1: locomotion and dysfunction score
Marmosets used in this experiment
A total of 10 marmosets that received the single regimen 
of MPTP were used in this behavioral experiment, which 
lasted for more than 1 year. Some of these marmosets 
continued to be used in the other four experiments in 
the present study.
Continuous measurement of locomotion as an 
objective, quantitative, and simple measure of 
immobility, one of the primary signs of Parkinsonism
The daily locomotion count of each marmoset in individ-
ual living cages was recorded continuously for 2 weeks 
before MPTP administration and for more than 1 year 
after the single regimen. An infrared motion sensor 
(O'Hara and Co., Tokyo, Japan) attached to the ceiling 
of each cage detected locomotion by measuring spatial 
shifts of thermal sources generated by the body parts 
of the marmosets by CIEA ACT scan computer system 
(Ando et al., 2008).
Dysfunction score as an overall and qualitative 
measure based on visual inspection to support the 
locomotion data
Experienced observers visually inspected gross behav-
ior at least once a week. The inspection was based on 
items listed on the CIEA dysfunction score form for the 




ID of MPTP-treated  
marmosetsb Control for MPTP-treated marmosets
Experiment 1: locomotion and  
dysfunction score
8 (10b) CM1b, CM2, CM3b, CM4, CM5,  
CM6, CM7, CM8, CM9, and CM14
Pre-MPTP level of each marmoset listed on the left side
Experiment 2: door-opening choice 
behavior for food reinforcement
4 CM1c, CM2, CM4, and CM14 Pre-MPTP level of each marmoset listed on the left side and additional 
MPTP-free marmosets (CM11, CM16, CM20, and CM22)
Experiment 3: apomorphine-induced 
circling behavior
6d CM2, CM4, CM5, CM6, CM7, and 
CM8
Additional MPTP-free marmosets (CM18, CM21, and CM25)
Experiment 4: brain MRI analysis 6e CM2, CM4, CM5, CM6, CM7 and 
CM8
Pre-MPTP level of each marmoset listed on the left side
Experiment 5: brain histology 4f CM4, CM6, CM8, and CM14 Additional MPTP-free marmosets (CM18 and CM32g)
aAll MPTP-treated marmosets in the present study received the single regimen of MPTP at cumulative-free base dose of 5 mg/kg, s.c., over three consecutive days in 
experiment 1.
bMarmosets CM1 and CM3 died 2.7 months after the MPTP-regimen (see text).
cPost-MPTP test in CM1 was performed 1 week before its sudden death. This marmoset appeared well enough to be tested at that time. Therefore, the test data were 
used in experiment 2.
dMarmosets with brains scanned by MRI in experiment 4 were used in experiment 3.
eBrains of only six marmosets were scanned because of limited MRI machine time.
fOnly four brains of the MPTP-treated marmosets were examined by tyrosine hydroxylase antibody immunohistochemical staining. Other brain was histologically analyzed 
in more detailed manner in other advanced MRI studies (Hikishima et al., 2015a; Hikishima et al., 2015b).
gData used and reported in previous study (Ando et al., 2017).
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common marmoset. The score included items related to 
PD-like signs, as well as other dysfunctions (Ando et al., 
2012). These items included: staying on the floor, lack of 
stimulus tracking, no biting, lack of facial expression, no 
squeak, resting tremor, moving tremor, jerky movements, 
immobility, hypoactivity, and catalepsy. Each of the 11 
items listed on the form was recorded as observed (one 
point) or not observed (0 points). The dysfunction score 
represents the total number of observed behaviors out of 
a maximum of 11 points.
Experiment 2: door-opening choice behavior for food 
reinforcement
Marmosets used in this experiment
Four marmosets that satisfied the criterion for estab-
lishment of door-opening choice behavior during train-
ing before the MPTP regimen were selected from 
those using in experiment 1. Choice behavior data in 
this MPTP-treated group were compared between the 
pre- and post-MPTP regimen to examine influences of 
MPTP on this behavior. A further four healthy and intact 
male marmosets with body weights and ages comparable 
to those of the MPTP group were used as the MPTP-
free group. They were treated in the same manner as 
were in the MPTP group, except that marmosets in the 
MPTP-free group did not receive MPTP.
Equipment
The multiple mailbox-type equipment consisted of 10 
small boxes, five of which were placed on top of the other 
five boxes (see Video 1, Supplemental digital content 1, 
http://links.lww.com/FBP/A3). Each small box was 4.5 cm 
high, 3.0 cm wide, and 4.5 cm deep. The equipment was 
temporarily placed in front of a marmoset in its individ-
ual living cage when training or testing was performed. 
A piece of sponge cake (a food piece) was placed inside 
each box before starting training or testing. This food 
piece was hidden from the marmoset by a black opaque 
door.
Choice behavior training
The door-opening choice behavior of each marmoset 
was trained using food reinforcement in the multiple 
mailbox-type equipment. When the marmoset pulled 
a knob attached to any of 10 doors using its fingers, 
the food piece was available unless it had previously 
been taken. Thus, the door-opening choice response to 
each of the 10 boxes was reinforced with a food piece. 
Experimenters visually observed and recorded every 
opening response by the marmoset. The choice of a box 
containing a food piece was termed a correct (reinforced) 
choice response, while that of a box not containing a food 
piece (because it had been already taken by the mar-
moset) was termed an incorrect (non-reinforced) choice 
response. The experimenters also recorded whether the 
marmoset obtained and ate, or failed to grasp, the food 
piece (termed a correct response with eating of a food 
piece and a correct response with missing of a food piece, 
respectively). All training sessions were terminated 
when all food pieces had been obtained by the marmo-
set, or after 5 minutes (whichever came first). The train-
ing was conducted once daily on, generally 3 days per 
week. Daily food (50 g/day of balanced diet, described 
in the Animals and husbandry section above) was pro-
vided to the marmosets after training as well as after the 
testing described below. Therefore, the food deprivation 
procedure typically applied to laboratory animals in food 
reinforcement experiments was not used in the present 
experiment. The marmosets were trained until they sat-
isfied the criterion for establishment of choice behavior, 
which was that all food pieces were obtained within 5 
minutes over 5 consecutive training days.
Testing of choice behavior before and after the 
single regimen of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-treated group
Once the marmosets had satisfied the criterion for 
establishment of choice behavior in the repeated train-
ing sessions, the pre-MPTP test was performed in the 
same manner as in the training sessions. This test was 
performed only once, at 0.5 months before the MPTP 
regimen.
The post-MPTP test was performed in the same man-
ner as in the pre-MPTP test in the same marmosets, at 
1.4 months after the MPTP regimen without any main-
tenance training. In these MPTP-treated marmosets 
(MPTP group), influences of MPTP on behavior were 
examined by comparing test data between the pre- and 
post-MPTP. Measurements of choice responses are 
described in the Statistical analysis section.
Testing of choice behavior in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine-free group
The stability of door-opening choice responses without 
maintenance training (as in the MPTP group) was con-
firmed using control marmosets in the MPTP-free group. 
Marmosets in the MPTP-free group were selected, 
trained, and tested in the same manner as the MPTP 
group. For control MPTP-free marmosets, no main-
tenance training was performed between the first and 
second test (separated by a 2-month period), which was 
comparable to marmosets in the MPTP group.
Experiment 3: apomorphine-induced circling behavior
Marmosets used in this experiment
Long-lasting but latent effects of MPTP at the behavioral 
level were examined by apomorphine-induced circling 
behavior in six MPTP-treated marmosets used in exper-
iment 1; brains of these marmosets were also scanned 
by MRI in experiment 4. Three other MPTP-free male 
marmosets were used as controls, and were healthy and 
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intact with body weights and ages comparable to MPTP-
treated marmosets.
Apomorphine preparation and administration
Apomorphine hydrochloride (Sigma-Aldrich Co.) was 
added to physiological saline just before its subcuta-
neous administration. The mixture then was prepared 
to pure solution using an ultrasonic crashing apparatus. 
Apomorphine at 0.13 mg/kg (2 ml/kg) or saline (2 ml/kg) 
was administered to each marmoset. This test dose of 
apomorphine was determined in pilot experiments using 
marmosets that received the present MPTP regimen, 
and no clear behavioral change or hyper-excitation was 
observed after administration of apomorphine at 0.06 and 
0.25 mg/kg s.c., respectively.
Equipment
A cylindrical chamber (40 cm in diameter and 65 cm high) 
was used. A transparent plastic cover was placed on top of 
the chamber to observe circling behavior, and to prevent 
the marmoset from jumping out. A cone was placed in the 
center of the circular floor to prevent the marmoset from 
crossing the center.
Measurement of circling behavior
Circling behavior was observed 14 months after the 
MPTP regimen. Five minutes after s.c. administration 
of apomorphine or saline, each marmoset was placed in 
the chamber. One circle was defined as a 360° full rota-
tion. The numbers of right and left circling were visually 
counted for 60 minutes.
Experiment 4: brain MRI analysis
Marmosets used in this experiment
Brains of six marmosets were scanned once 5–6 months 
before, and 2 months after, the MPTP regimen, to obtain 
T1- and T2-weighted images and T1 and T2 relaxation 
times. The weighted images and relaxation times were 
obtained sequentially during the same scan. Not all mar-
mosets were scanned because of the limited availability 
of MRI machine time. Just before and during each MRI 
scan, the marmosets were deeply anesthetized and care-
fully monitored, as described previously (Hikishima et al., 
2011; Hikishima et al., 2013).
MRI equipment
A 7T Biospec 70/16 MRI system (Bruker Biospin GmbH, 
Ettlingen, Germany) with integrated transmitting and 
receiving coils 62 mm in diameter was used for the brain 
scan.
T1- and T2-weighted images
For qualitative inspection, T1- and T2-weighted images 
were obtained before and after the MPTP regimen. 
Images in the present study were acquired and reported 
as described previously (Hikishima et al., 2011).
T1- and T2-relaxation time measurements
Different from visual inspection of the above images, 
objective and quantitative values (ms) of T1 and T2 
relaxation times, within the same scan, were obtained 
before and after the MPTP regimen. T1 relaxation times 
were acquired using the saturation recovery spin echo 
method with variable rapid acquisition and relaxation 
enhancement (RARE) with multiple repetition times 
(effective echo time: 18  ms; repetition times: 500, 744, 
1032, 1384, 1836, 2468, 3527 and 8000 ms, in that order; 
RARE factor: 4, field-of-view: 23.0 × 34.0 mm on a 128 
× 128-matrix; slices: 12, each 1.2  mm in thickness; and 
total scan time: 7 minutes 48 seconds). T2 relaxation time 
values were acquired using the multi-slice and multi-spin 
echo sequence method (echo times: 9, 18, 27, 37, 46, 55, 
64, 73, 82, 91, 101, and 110 ms, in that order; repetition 
time: 3000  ms; total scan time: 4 minutes 48 seconds; 
field-of-view and slices: the same as for the T1 relaxation 
time measurement).
Regions of interest (ROIs) for the caudate and putamen 
in the striatum were drawn as circles with a radius of 
three pixels (0.54  mm) on the A 9.0 slice of the atlas 
(Newman et al., 2009), as shown in the upper part of Fig. 
5; T1-weighted images of a marmoset were taken before 
MPTP administration. ROIs for the substantia nigra 
(SN) compacta and SN reticulata were determined with 
an ellipse of 15 pixels (2.70 mm) of the major axis and six 
pixels (1.08 mm) of the minor axis on the A 3.5 slice of 
the same atlas, as shown in Fig. 5. The upper half of the 
ellipse in the cranial direction was determined as the SN 
compacta and the lower half, in the caudal direction, was 
the SN reticulata.
Experiment 5: brain histology
Marmosets used in this experiment
After completing experiments 1–4, four marmosets (CM4, 
CM6, CM8, and CM14) were deeply anesthetized with 
an intraperitoneal administration of sodium pentobar-
bital (100 mg/kg of somnopentyl; Kyoritsu Seiyaku Co. 
Ltd, Tokyo, Japan) and euthanized by exsanguination. 
Brains of these marmosets were used for brief histology 
in the present study. Detailed histological analysis had 
already been reported as background data for advanced 
MRI studies using other marmosets that received the 
MPTP regimen used in this study (Hikishima et al., 
2015a; Hikishima et al., 2015b). Therefore, histological 
analysis in the present study was performed only to con-
firm gross brain damage induced by the present MPTP 
regimen.
The stained brains of MPTP-treated marmosets were 
compared to the brains of two MPTP-free male marmo-
sets. One (CM32) had been reported in a previous study 
(Ando et al., 2017). The same staining procedure was 
used in the previous and the present studies.
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Preparation of the brain sample
Brains were removed and fixed in 20% buffered for-
maldehyde and embedded in paraffin. The coronal sec-
tion (thickness: 15 μm) was prepared + 10 mm from the 
interaural line (+6.1 mm from the bregma) by reference 
to the brain atlas (Yuasa et al., 2010). This section was 
selected because the caudate and putamen were clearly 
distinguishable in the striatum of MPTP-free marmoset 
brains. Immunohistochemical staining with TH anti-
body (1:500, mouse anti-tyrosine hydroxylase MAB318; 
Merck Millipore Co., Billerica, Massachusetts, USA) was 
performed using an automated immunostainer (Bond-
MAX; Leica Biosystems Co., Mount Waverley, Australia). 
Images were captured and generated using an upright 
microscope (Axio Imager; Carl Zeiss Inc., Thornwood, 
New York, USA).
Quantitative analysis of stained area
Coronal images of the brains of three marmosets (CM4, 
CM6, and CM8) that received the single MPTP reg-
imen, and of the brains of two MPTP-free marmosets, 
were quantitatively analyzed using NIH ImageJ software 
(https://imagej.nih.gov/ij/), as described previously (Ando et 
al., 2017). Each brain image was analyzed by the software 
in the following manner: (1) selecting ‘Image → Color 
→ Split Channels' and using only the blue split image, 
(2) setting the length scale to mm, (3) tracing the out-
line of the whole coronal brain image as the ROI, (4) 
selecting ‘Image → Adjust → Threshold' and adjusting 
the minimum threshold to 0 and the maximum thresh-
old to 100 (because these settings yielded clear images of 
the striatum in the MPTP-free marmoset brain without 
interference by other areas), and (5) selecting ‘Analyze 
→ Measure'. With these settings, the area of the image 
detected under the fixed thresholds (in pixels) from the 
whole coronal brain was calculated in mm2. To address 
density differences among brain images obtained from 
different tissue preparations, simplified validation was 
performed. Each ROI (1.0 × 1.0 mm) was placed in the 
right and left cortex of the same split blue coronal images 
and measured in mm2, with or without thresholds.
Statistical analysis
All averaged data are expressed as means and SDs. In the 
statistical analysis, P ≤ 0.05 was considered statistically 
significant.
Experiment 1
No statistical analysis was performed, although quantita-
tive data are graphically presented in Figs. 1 and 2.
Experiment 2
Data of door-opening choice responses were analyzed 
in terms of several parameters, as follows: total no. of 
responses: no. of responses in the daily session; total 
responses per minute: no. of responses/session time in 
minutes (time to take 10 food pieces or reaching the 
5-minute session-time limit, whichever came first); total 
correct responses (%): 100 × no. of correct responses 
including both eating food and missing (failure to grasp) 
food pieces; correct responses with eating of food piece 
(%): 100 × no. of correct responses with eating of food 
piece/no. of total responses; and correct responses with 
missing of food piece (%): 100 × no. of correct responses 
with missing of food piece/no. of total responses. All of 
these measures, presented in Fig.  3, were compared 
between the post-MPTP and pre-MPTP tests in the 
MPTP group (n = 4), and between the second and the 
first tests in the MPTP-free group (n = 4). The percent 
data were not subjected to arc-sin transformation; instead, 
they were analyzed statistically using two-tailed Student 
paired t-test in Excel 2011 software (Microsoft Corp., 
Redmond, Washington, USA), as per the other non-per-
cent data obtained in this experiment.
Experiments 3, 4, and 5
In experiment 3, statistical analysis was not performed, 
but quantitative data of apomorphine-induced circling 
behavior (no. of 360° full rotations) are graphically pre-
sented in Fig. 4. In experiment 4, all T1 and T2 relax-
ation times (ms) were obtained from the ROIs in the 
striatum (putamen and caudate) and the SN (compacta 
and reticulate) in each brain hemisphere. Values for both 
hemispheres were averaged for each ROI after confirm-
ing the appropriateness of such averaging by analysis of 
variance (ANOVA) testing using SPSS statistical software 
(IBM Corp., Armonk, New York, USA). The T1 and T2 
relaxation times for each ROI in Fig. 5 were compared 
between the post- and pre-MPTP tests (n = 6 for each) 
using two-tailed Student's paired t-test in Excel 2011 
software. When examining the relationship between 
the T1 relaxation time and apomorphine-induced cir-
cling behavior, the T1 value of each ROI was subjected 
to Pearson's correlation analysis in terms of apomor-
phine-induced circling behavior in either direction using 
SPSS. In experiment 5, only representative coronal brain 
photos are presented in Fig.  6. Histologically stained 
areas (mm2) were also analyzed using ImageJ. The corre-
lation between histological areas of the two coronal hem-
ispheres and circling directions (n = 3) was calculated 
using SPSS.
Results
Experiment 1: baseline locomotion and dysfunction 
score
Changes in the daily locomotion of each marmoset 
treated with the single regimen of MPTP at the cumu-
lative-free base dose of 5  mg/kg s.c. on three consecu-
tive days are presented in Fig. 1. The locomotion count 
was expressed as the percentage relative to the baseline 
of each marmoset (the preceded 1-week mean of daily 
counts recorded during the 2 weeks before the single 
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regimen). Four marmosets in the top blocks were rela-
tively stable, with low locomotion counts for 8 weeks or 
more after the MPTP regimen, whereas the other four 
marmosets in the middle blocks showed spontaneous 
recovery over several weeks. Two marmosets showed 
low and stable levels of locomotion, similar to the four 
marmosets in the top blocks, but these animals died so 
their data are not presented in the figure. Marmoset CM1 
died 2.7 months after the single MPTP regimen, with 
occasional vomiting and lying down exhibited for a few 
days before death. According to the autopsy, there was 
an abnormality in the digestive system. Marmoset CM3 
was euthanized by exsanguination under deep anesthesia 
by sodium pentobarbital at 100 mg/kg, i.p., because this 
marmoset gradually showed decreased food intake, body 
weight loss, and physical weakness for an undetermined 
reason.
The left and middle bottom blocks represent mean 
counts with SDs from eight marmosets, excluding the 
two dead marmosets, over 2 months (60 days) and over 
more than 18 months (72 weeks), respectively, after the 
single MPTP regimen. Mean locomotion counts indi-
cated gradual recovery over days, weeks, or months, 
but did not attain the mean pre-MPTP baseline levels 
(100%) after 18 months. To explore influences of MPTP 
on the circadian rhythm of locomotion, the percentages 
of locomotion at night (21:00–09:00 hours) in terms of 
total daily (24-hour) locomotion were calculated, and 
are shown in the right bottom graph. This percentage 
at night increased significantly in some marmosets for a 
few weeks after the single regimen. In some cases, these 
increases went back to the zero percent level, but gener-
ally the levels remained high for several weeks after the 
single regimen compared to pre-MPTP levels (Fig. 1).
Fig. 1
Long-term changes in daily locomotion of common marmosets that received a single regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP). Decreased locomotion is an objectively quantifiable measure of immobility, one of the main signs of Parkinsonism. This measure is 
considered sensitive and useful for preclinical evaluations of drug therapy and brain transplantation of neural cells in the marmoset of Parkinson's 
disease model. A single MPTP regimen is convenient for preclinical evaluation studies if the decreased level of locomotion is properly charac-
terized over the long-term. In the present single regimen, subcutaneous (s.c.) MPTP at free base doses (not included HCl in its calculation) of 
2, 2, and 1 mg/kg on days 0–2, respectively, was administered to 10 marmosets. The locomotion count of each marmoset in its individual living 
cage was recorded continuously, every hour for 1 year or more, after the single MPTP regimen (cumulative dose of 5 mg/kg). The count was 
expressed as the percentage relative to the pre-MPTP baseline level of each marmoset, which was defined as the preceded 1-week mean of daily 
counts recorded during the 2 weeks before single MPTP regimen. Downward arrows represent the 3-day MPTP regimen. Each of the upper eight 
blocks in this figure indicates the locomotion count of each of eight marmosets. Data for the other two marmosets are not presented in this figure 
because these marmosets died 2.7 months after the MPTP regimen (see text for explanation). The bottom left and middle blocks represent means 
and standard deviations of the eight marmosets over 60 days and 70 weeks, respectively. The bottom right block indicates the percentages of 
nightly locomotion (21:00–09:00 hours) as proportions of the daily total locomotion of each marmoset.
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Gross behavioral observation revealed various changes, 
including the development of PD-like signs such as 
immobility, lack of facial expression, and jerky move-
ments after the single regimen of MPTP, but these 
changes were variable across animals and time. Total 
dysfunction scores and extent of moving tremor (motion 
tremor) >40 weeks after the regimen are shown in 
Fig.  2. The dysfunction scores of MPTP-treated mar-
mosets, based on visual inspection of gross behavior, 
increased after the MPTP regimen. The mean scores 
did not decrease to pre-MPTP levels even ≥40 weeks 
after the regimen. For reference, total dysfunction score 
1 week before MPTP regimen was 1.1 and 0.6, each 
mean and SD, respectively. Of the observational items, 
moving tremor was one of the most distinct and clearly 
observable signs, exhibiting minimal variability across 
observation times within marmosets. Once the moving 
tremor appeared in a specific marmoset, this persisted 
consistently for a relatively long period. Therefore, 
moving tremor data are especially significant, and are 
presented here in addition to the total dysfunction 
scores. As shown in Fig. 2, the ratio for moving tremor 
ranged between 0.0 (moving tremor not observed in any 
marmoset) and 1.0 (moving tremor observed in all eight 
marmosets). Moving tremor persisted in more than half 
of the eight marmosets observed weekly for 40 weeks 
after the single regimen of MPTP. For reference, ratio 
of marmosets displayed moving tremor 1 week before 
MPTP regimen was 0.0 and 0.0, each mean and SD, 
respectively.
Experiment 2: door-opening choice behavior for food 
reinforcement
Training
Marmosets were trained for door-opening choice behav-
ior for several months. Marmosets that satisfied the 
establishment criterion for this behavior, as described in 
the Methods, completed the pre- and post-MPTP tests 
as the MPTP group (n = 4). Marmosets in the MPTP-
free group that satisfied the same establishment criterion 
were also selected for the first and second tests (n = 4). An 
example of door-opening choice behavior is presented in 
Video 1 (Supple mental digital content 1, http://links.lww.
com/FBP/A3).
Fig. 2
Changes in dysfunction scores after the single MPTP regimen. The dysfunction score represents the weekly mean and SD values in eight mar-
mosets over 40 weeks, excluding two marmosets which died in the middle of the experiment. The score data were based on visual inspection by 
experienced observers according to the items of the Central Institute for Experimental Animals (CIEA) dysfunction score. The score was com-
posed of 11 items related to Parkinsonism and some other signs of dysfunction in marmosets after the MPTP regimen. These items include mov-
ing tremor, resting tremor, jerky reaction, immobility, catalepsy, hypoactivity, lack of facial expression, lack of squeaking, lack of eye-tracking, lack of 
biting a pencil, and lying on the floor. Each item was recorded as observed (one) or not observed (0). Thus, the dysfunction score was defined as 
the total number of observed items (max = 11). For reference, total dysfunction score 1 week before MPTP regimen (indicated as ‘−1' week on 
the horizontal axis) was 1.1 and 0.6 (mean and SD). The moving tremor, one of the most clearly evident signs of PD, is represented as the ratio of 
marmosets with moving tremors out of the total eight marmosets, with weekly mean and SD data. The ratio for the moving tremor ranged between 
0.0 (moving tremor not observed in any marmoset) and 1.0 (moving tremor observed in all eight marmosets). For reference, the ratio of marmosets 
displayed moving tremor 1 week before MPTP regimen was 0.0 and 0.0 (mean and SD). Downward arrow represents the 3-day MPTP regimen. 
PD, Parkinson's disease.
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Comparison between the post- and pre-1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine tests of 
door-opening choice behavior in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine group
Results of food-reinforced choice behavior in the MPTP 
group are presented in the upper graph of Fig.  3. The 
total number of door-opening choice responses in the 
post-MPTP test did not change significantly after the 
single regimen of MPTP, even though 2 months had 
passed between the pre- and post-MPTP tests without 
maintenance training. On the other hand, there was a 
decrease in the total number of responses per minute in 
the post-MPTP test compared to the pre-MPTP test.
The percent total correct responses in the post-MPTP 
test did not significantly differ from the pre-MPTP test 
(data not shown in Fig. 3). On the other hand, the per-
cent correct responses when food pieces were eaten 
decreased significantly compared to the pre-MPTP test. 
The percent correct responses when food pieces were 
missed (failed to be grasped) increased significantly 
compared to the pre-MPTP test. Eating and missing of 
food pieces were confirmed by visual inspection by the 
Fig. 3
Influences (direct and indirect effects) of MPTP on food-reinforced door-opening choice behavior in marmosets, using mailbox-type equipment. 
Before performing the tests described below, marmosets were repeatedly trained for choice behavior for a food piece, obtained by opening one 
of 10 opaque doors in which a food piece was placed inside (unless it had already been taken). The MPTP-treated marmosets and MPTP-free 
marmosets (n = 4 in each group) that satisfied the choice behavior establishment criterion were selected and used for two tests, which were sep-
arated by a 2-month interval. The two tests were named pre- and post-MPTP tests in the MPTP group and the first and second tests in the MPTP-
free group. The marmosets in the MPTP group were selected from those that received the single regimen of MPTP in experiment 1. Maintenance 
training was not provided between the two tests in either group. The total response represents the number of total door-opening responses by 
each marmoset in one test session, in which all 10 food pieces had been obtained or 5 minutes had elapsed (whichever came first). Response 
percentages for each measure are expressed relative to the total number of responses. A correct response was defined as the choice of a box 
that contained a food piece. The mean and SD data for measure are expressed in the graphs. Within-group data for each measure were compared 
between the two behavioral tests using a two-tailed paired Student t-test (*P ≤ 0.05).
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experimenters. The missing indicates impairment of 
skilled finger motion after the single MPTP regimen.
Comparison between the first and second tests of 
door-opening choice behavior in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine-free group
As shown in the lower graph of Fig. 3, the four measures 
of door-opening choice behavior and the total correct 
responses (%; data not shown) did not change signif-
icantly between the first and second tests. No mainte-
nance training was given to marmosets between the two 
tests (2 months apart), and stability of this door-opening 
choice behavior was observed in the MPTP-free marmo-
set group. Therefore, changes in the MPTP group are 
likely associated with MPTP administration.
Experiment 3: apomorphine-induced circling behavior
The six marmosets used in this experiment showed mov-
ing tremors in their individual living cages over 1 year 
after the single regimen of MPTP. These marmosets 
did not show any tendency for circling behavior in their 
individual living cages over a long period of observation. 
When apomorphine was administered at 0.13 mg/kg s.c., 
either right or left circling (one circle = 360° full rotation) 
was observed in the cylindrical chamber (Fig.  4). The 
direction of circling differed depending on the marmo-
set, although all marmosets had previously received the 
same MPTP regimen by the subcutaneous route. On 
the other hand, they did not show any clear circling after 
saline administration. In MPTP-free marmosets, no such 
circling tendency as in the case of MPTP-treated marmo-
sets was observed after subcutaneous administration of 
either apomorphine at 0.13 mg/kg or saline. The circling 
behavioral data were analyzed in relation to the MRI 
data, as described in of experiment 4.
Experiment 4: MRI analysis
Global and qualitative brain images of six marmosets 
were compared between pre- and post-MPTP regimen 
by visual inspection (data not shown). No qualitative 
Fig. 4
Circling behavior of marmosets in a cylindrical chamber. The number of 360° full rotations was recorded in the MPTP and MPTP-free groups 
within 60 minutes after s.c. administration of apomorphine at 0.13 mg/kg or saline. Circling behavior in the MPTP group was recorded at 14 
months after the single MPTP regimen in experiment 1.
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Fig. 5
MRI analysis of marmoset brains. In the upper part, regions of interest (ROIs) on the striatum (putamen and caudate) and the substantia nigra 
(compacta and reticulata) are delineated on the T1-weighted coronal images of an MPTP-free marmoset. In the lower graphs, means and SDs of 
T1 relaxation times (ms) are presented on each ROI in the pre- and post-MPTP scans. MRI scans were performed for six marmosets, 4–5 months 
before and 2 months after, the MPTP regimen in experiment 1. The mean T1 relaxation times on each ROI were compared between pre- and post-
MPTP scans using the two-tailed paired Student t-test (*P ≤ 0.05).
Fig. 6
Histology of marmoset brains. Tyrosine hydroxylase immunohistochemical staining was performed on the coronal slice taken +10 mm from the 
interaural line (+6.1 mm from the bregma) of a representative brain of an MPTP-free marmoset, and from marmoset that received the present 
MPTP regimen in experiment 1.
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difference was visually evident in the coronal views of 
T1- and T2-weighted images between pre- and post-
MPTP administration, with a focus on ROIs in the stri-
atum (putamen and caudate) and the SN compacta and 
SN reticulata.
Next, T1- and T2-relaxation times (ms) for the above 
ROIs were compared between pre- and post-MPTP reg-
imen. The T1- and T2-values for each ROI were aver-
aged between the right and left hemispheres of each 
marmoset brain. As shown in the bottom graph of Fig. 5, 
T1 values averaging the ROIs of the two hemispheres 
significantly increased in the putamen, caudate, and SN 
compacta in the post-MPTP scan compared to the pre-
MPTP scan, but did not increase significantly in the SN 
reticulata. The average T2 values of both hemispheres 
for all post-MPTP ROIs did not differ significantly from 
pre-MPTP values (data not shown).
Concerning the appropriateness of averaging the val-
ues between the right and left hemispheres, three-way 
ANOVA [factor 1, timepoint (pre- and post-MPTP); fac-
tor 2; ROIs; and factor 3; laterality (right and left)] did not 
reveal any significant difference in the laterality [n = 6, F 
(7, 80) = 0.50, NS the T1 values; n = 6, F (7, 80) = 0.04, NS 
for the T2 value].
In the analysis of the relationship between the T1 values 
and apomorphine-induced circling behavior, the correla-
tion coefficients between the post-MPTP T1 values in 
the two brain hemispheres and the number of circling 
behaviors in either direction were calculated. A signif-
icant correlation was observed between the T1 value 
of the right SN compacta in the post-MPTP value and 
the right circling behavior (n = 6, r = 0.85, P < 0.05). On 
the other hand, no significant correlation was observed 
between circling in either direction and any post-MPTP 
T1 value in the striatum (putamen and caudate) of either 
hemisphere.
Experiment 5: brain histology
A representative coronal slice of an MPTP-free intact mar-
moset shows dopaminergic (catecholaminergic) neurons 
in the putamen and caudate of the striatum (Fig. 6). A rep-
resentative slice of a marmoset that received the present 
single MPTP regimen was indicative of neural loss in the 
striatum as shown in the same figure. In the present study, 
the coronal slices of four marmosets (CM4, CM6, CM8, 
and CM14) that received the same MPTP regimen were 
obtained and examined histologically. The other mar-
moset brain in the present study was made available for 
advanced MRI studies (Hikishima et al., 2015a; Hikishima 
et al., 2015b), in which detailed histological analysis was 
performed to validate the MRI results.
Based on quantitative analysis using ImageJ software in 
the present study, stained coronal images of the brains 
of four marmosets that received the present MPTP regi-
men were captured and digitalized (by pixels) as well as 
in the case of the brains of two MPTP-free marmosets. 
The chosen thresholds (minimum = 0 and maximum = 
100) allowed for visualization of only the striatum in the 
MPTP-free marmoset brains. These areas were 37.4 and 
43.5  mm2 in MPTP-free marmosets CM18 and CM32, 
respectively. However, areas within the same thresholds 
ranged from 0.1 to 6.1 mm2 in the four marmosets that 
received the MPTP regimen.
Using the same software, TH-stained coronal areas in the 
right and left hemispheres were measured separately in 
three marmosets (CM4, CM6, and CM8) received MPTP 
regimen and used in the apomorphine-induced circling 
behavior experiment. There was no statistically signifi-
cant correlation between the stained coronal area in either 
hemisphere and circling behavior in either direction.
Discussion
Objectively recorded locomotion as a measure of 
immobility to evaluate protective effects against 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity for 
future preclinical treatments
The present study investigated the baseline locomotion 
behavior over a period of several months of marmosets in 
individual living cages after receiving a single regimen 
of 5 mg/kg s.c. MPTP over three consecutive days (The 
MPTP dose was calculated and expressed as the free 
base excluding HCl). The purpose of this experiment 
was to characterize the usefulness and limitations of this 
behavioral baseline for future preclinical evaluations of 
drug therapies or neural cell transplantations, in terms 
of protection against MPTP toxicity. Within this frame-
work, the single regimen of MPTP is considered prefer-
able for efficacy evaluation compared to repeated MPTP 
regimens over week-long intervals, because repeated 
and multiple MPTP regimens may result in unpre-
dicted complications. The single MPTP regimen is also 
desirable because the delivery of treatment regimens is 
time-consuming for experimenters, with important safety 
considerations associated with MPTP toxicity. However, 
if the MPTP-induced PD model is used to investigate 
the acute dose effects of test drugs, repeated MPTP reg-
imens can be used until marmosets show marked and 
desirable PD-like manifestations.
To the best of our knowledge, no previous reports have 
continuously recorded the locomotion of PD model mar-
mosets in individual living cages (not socially housed) 
for more than 1 year after a single regimen of MPTP. 
Other studies have performed detailed characteriza-
tions of MPTP-treated marmosets in terms of motor and 
non-motor functions, such as olfaction and social inter-
action (Philippens et al., 2010; Phillips et al., 2017). It is 
important to compare these functions between marmo-
sets that received full versus partial MPTP dose regi-
mens to obtain a basic understanding of the marmoset 
model. On the other hand, our study described a practical 
model for preclinical evaluation of medical treatments, 
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in which multiple factors with complicated relationships, 
such as those involved in social interaction, and multiple 
regimens of MPTP administration were not considered.
Decreased levels of locomotion are considered a measure 
of immobility, one of the main signs of Parkinsonism. In 
preclinical evaluation studies, a clear conclusion regard-
ing the efficacy of a given medical treatment is required, 
although that conclusion is based on specific experimen-
tal conditions. A decreased level of locomotion is con-
sidered an objective, quantitative, simple, and sensitive 
measure for characterizing the protective effects of drugs 
against MPTP toxicity (Ando et al., 2008). However, the 
MPTP-induced decrease in baseline locomotion showed 
some fluctuations and spontaneous recovery among the 
animals in this study. The usefulness and limitations 
of the locomotion measure were clarified by observing 
these changes over a period of months. Evaluation tests 
should be performed within a 2-month period after the 
MPTP regimen: two of the 10 marmosets in this study 
died within 2.7 months. In future studies examining 
protective effects of medical treatments against MPTP 
toxicity, preclinical evaluations could employ analyses 
such as area under the curve (x-axis: days after MPTP 
regimen; y-axis: locomotion level) between an MPTP 
plus vehicle control group and an MPTP plus preclinical 
treatment group.
Other points for consideration regarding locomotion 
measurement
The locomotion counts of marmosets were continuously 
recorded for 24 hours over consecutive days, weeks, and 
months in this study. In the control MPTP-free mar-
mosets, high counts were consistently recorded during 
light-on daytime but very low levels or almost no loco-
motion were recorded at night, indicative of a circadian 
rhythm similar to humans rather than rodents. Daily 
locomotion counts were stable for multiple days before 
MPTP administration, with some variability across 
marmosets. When the daily locomotion counts for each 
marmoset were expressed as percentages of the mean 
daily counts for a predetermined period (e.g. for 1 week) 
before the MPTP regimen, the percentage locomotion 
measure represented a stable behavioral baseline with 
less individual variability among marmosets. In MPTP-
treated marmosets, the percentage locomotion counts 
decreased for several weeks, with less variability within 
all marmosets when expressed as the percentages rather 
than actual locomotion counts. Therefore, the decreased 
level of locomotion in the MPTP-treated marmoset is 
considered a valid, objective, quantitative, and stable 
behavioral baseline.
Although the baseline locomotion was stable within a 
limited period, spontaneous recovery to pre-MPTP lev-
els was observed in some marmosets. It is possible that 
the present MPTP regimen did not induce long lasting 
damage to the dopaminergic neural system in marmosets. 
Thus, the remaining neural system in the brains of these 
marmosets may be able to compensate for the damaged 
system, leading to behavioral recovery. Other individ-
ual differences in recovery among marmosets may be 
related to variations in the metabolic processes involved 
in converting MPTP to MPP+ in dopaminergic cells of 
the SN, although many other factors may be involved in 
individual differences in MPTP toxicity (Przedborski 
and Jackson-Lewis, 1998; Bajpai et al., 2013). The indi-
vidual differences and recovery in the present model 
may provide important information for understanding 
the etiology of PD and for considering rehabilitation 
methods for PD patients by activating remaining neural 
networks. Aside from the recovery issue, two marmosets 
died or were euthanized during the study. The cause of 
their gradual weakening was thought to be MPTP tox-
icity, although all marmosets were provided with several 
weeks of intensive care. These two marmosets were con-
sidered more sensitive than the others in terms of toxicity 
to MPTP or MPP+.
It should also be noted that the proportion of locomotion 
at night increased for several weeks after the MPTP reg-
imen in some marmosets. This phenomenon persisted 
for a limited period (several weeks) after the MPTP regi-
men, but is reminiscent of the sleep disturbances seen in 
PD patients with dopaminergic neural activity changes 
(Barraud et al., 2009).
Parkinson's disease like signs observed based on the 
dysfunction score
Various PD-like and other signs of dysfunction were 
measured in this study. Monitoring of these signs was 
considered a secondary purpose of our present study. 
PD-like signs in marmosets that received MPTP have 
already been reported in detail previously (Jenner et al., 
2000; Fox and Brotchie, 2010).
Dysfunction scores in the present study increased 
for several weeks after the MPTP regimen, and then 
decreased but remained high for more than 40 weeks 
after single regimen of MPTP. The increased level of 
dysfunction (subjectively observed) is in accordance with 
the decreased level of locomotion (objectively meas-
ured). Visually observable PD-like signs in the present 
study were scored as ‘yes'or ‘no'by observers. Among 
the various signs, moving tremor (motion tremor) is one 
of distinct PD-like signs in MPTP-treated marmosets, 
although the resting tremor reported in PD patients was 
hardly observed in MPTP-treated marmosets.
Although objectively recorded locomotion is considered 
preclinically useful as a measure of immobility, other 
PD-like signs should be considered. Visual inspection of 
the general and gross behavior of experimental animals by 
experienced observers is important and useful in preclin-
ical studies (Nomoto et al., 1998; Fox and Brotchie, 2010). 
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Without this, it may be difficult to determine whether 
increased marmoset locomotion reflects an improvement 
due to treatment or merely an adverse reaction (such 
as hyper-sensitization or dyskinesia) (Ando et al., 2014). 
Detection of genuine therapeutic recovery from objec-
tively measurable immobility requires evaluation of total 
and general behavioral signs as in the present dysfunc-
tion score.
Food-reinforced choice behavior
Influences (direct and indirect effects) of MPTP on 
door-opening operant behavior were investigated in mar-
mosets that received the MPTP regimen. Initially, we 
expected that some types of cognitive impairment would 
be detected in MPTP-treated marmosets using the pres-
ent behavioral method (Vezoli et al., 2011). However, the 
correct response rate (%) in the post-MPTP test (a possi-
ble measure of cognitive impairment) did not show a sta-
tistically significant decrease compared to the pre-MPTP 
test. Therefore, cognitive impairment in the MPTP-
model marmosets was not detected using the present 
method. However, impairment of the skilled motion of 
fingering was detected based on the higher percentage 
of correct responses with missed (failure to grasp) food 
pieces. Slowed motion in the present choice behavior was 
also detected at 3 months after the MPTP regimen, as 
shown by the decrease in total responses per minute in 
the MPTP group.
In the MPTP-free group, no significant change was 
detected in any measure between the first and second 
tests, which were separated by 3 months. Therefore, the 
learning behavior was well-maintained during this period 
without any maintenance training. Thus, changes in 
measures in the MPTP group observed after the MPTP 
regimen compared to those before the regimen were not 
related to time-dependent changes or the lack of main-
tenance training between the two tests, but instead to 
influences of MPTP on behavior.
Food-reinforced learning behavior using the present 
mailbox-type equipment was established in a limited 
number of training sessions within a few months, and 
without food deprivation. The criterion for establishment 
of this behavior was not as strict as in our previous oper-
ant behavioral studies of the rhesus monkey and rat. In a 
delayed matching-to-sample experiment using the rhesus 
monkey, and a two-lever drug discrimination experiment 
using the rat (under water and food deprivation condi-
tions, respectively), the behavior establishment criterion 
was set at 80% correct responses over several consecutive 
daily sessions (Ando and Yanagita, 1992; Ando et al., 2003). 
Based on these results, we established several liquid-re-
inforced operant behaviors in the marmoset using the 
modified test chamber originally designed for the rat. In 
this way, it was possible to establish similar lever-press-
ing operant behavior in the marmoset. However, it was 
not easy to obtain stable baseline behavior in this small 
primate during similar tasks given to the rhesus monkey 
and rat. This may be because the marmoset is behavio-
rally restless and very sensitive to external stimuli. These 
behavioral traits make it difficult for the marmoset to 
concentrate on a specific task during experimental ses-
sions. It should also be noted that some degree of food or 
water deprivation are required to establish stable operant 
baseline behavior in laboratory animals, but deprivation 
above a certain limit is not appropriate for the marmoset 
because this small monkey species is likely to be physi-
cally weaker than the rhesus monkey and rat after depri-
vation. Furthermore, the deprivation procedure resulting 
in physical weakness in marmosets may not be ethically 
appropriate.
We used a simple choice task with neither deprivation 
nor strict behavior establishment criterion. In laboratory 
animal experiments, cognitive functions must be exam-
ined according to motor responses that differ from those 
in humans, in which verbal responses and minimum 
motor functions can be used based on an experimenter's 
oral instructions. Motor functions play important roles 
in cognitive function tests in laboratory animals, such as 
maze learning and delayed matching-to-sample tests; our 
present behavioral test is situated in between these two 
tests in terms of the contribution of motor functions. In 
addition, other monkey species with a higher tolerability 
for deprivation procedures and high concentration ability, 
such as the macaque monkeys, may be more appropriate 
to examine higher order cognitive functions using behav-
ioral methods. The rationale for assessing choice behav-
ior in our experiments was based on the purpose of our 
study, that is, to investigate multiple behaviors (including 
those affected by motor dysfunction) in MPTP-treated 
marmosets.
Apomorphine-induced circling behavior as a possible 
measure of asymmetrical neural damage in the brain 
hemispheres
Persistent but latent behavioral influences of MPTP 
were examined in this study based on apomorphine-in-
duced circling behavior. More than 1 year after the 
MPTP regimen, right or left circling of the marmosets 
in a cylindrical chamber was observed after subcutane-
ous administration of apomorphine. Using 6-hydroxi-
dopamine (another dopaminergic neurotoxin), circling 
behavior has been extensively studied in both rodents 
and marmosets (Przedborski et al., 1995; Ekesbo et al., 
2000; Eslamboli, 2005). Since 6-hydroxidopamine does 
not pass the blood-brain barrier, this toxin must be 
infused directly into the brain. When 6-hydroxidopamine 
is infused into the nigrostriatal dopaminergic neurons 
in either brain hemisphere, the neurons are specifically 
damaged on that side. Thus, denervation hypersensi-
tivity occurs at the dopaminergic receptors only on the 
damaged side. When apomorphine (a dopaminergic 
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receptor agonist) is peripherally administered to labora-
tory animals with unbalanced neural brain damage, the 
behavioral manifestation is contralateral circling, which 
is attributable to hyper-stimulated dopaminergic recep-
tors on the damaged brain side. In our present study, 
MPTP was not infused into either brain hemisphere but 
was administered peripherally (s.c.). Thus, MPTP was 
expected to damage the dopaminergic neurons in both 
brain hemispheres equally. However, either right or left 
circling, which varied among the MPTP-treated marmo-
sets, was observed after subcutaneous administration of 
apomorphine. Furthermore, right circling correlated sig-
nificantly with the post-MPTP T1 value in the right SN 
compacta. Therefore, this circling may be attributable to 
asymmetrical dopaminergic neural activity in the brain 
hemispheres. Although the relationship between circling 
behavior and neural imbalance is interesting, the implica-
tion of the T1 value increase in the SN compacta remains 
unclear, and asymmetrical neural damage to the two 
brain hemispheres in the present MPTP-treated marmo-
sets was not detected by TH histology. Further studies 
are required to explore relationship between this circling 
behavior and imbalanced brain damages. We expect that 
apomorphine-induced circling behavior may play a role 
in MPTP-treated marmosets as a sensitive behavioral 
probe to detect asymmetrical neural brain damage only 
if the other background data are to be more accumulated.
MRI analysis of neural brain damage
Two MRI studies have been already performed on mar-
mosets that received the present MPTP regimen, to 
detect neural damage caused by the peripheral admin-
istration of MPTP. In these already published reports, 
voxel-based morphometry showed that the volumes of 
SN and the locus coeruleus decreased after the pres-
ent MPTP regimen (Hikishima et al., 2015a). Another 
study using diffusion tensor analysis and tractography, 
on the same MPTP-treated marmosets used in the 
present study, revealed fiber disruption in the nigrostri-
atal pathway from the SN to the striatum (Hikishima et 
al., 2015b), backed by histological evidence, in marmo-
sets that received the present MPTP regimen. These 
two studies were started after the present MRI analysis 
using only T1 and T2 relaxation times. Therefore, the 
basic and grounded data on these relaxation times in the 
present study was considered to be worth reporting here 
although the order was the other way around.
When the marmoset brains were scanned via 7T-MRI, 
neither T1- nor T2-weighted post-MPTP images were 
visually different from the pre-MPTP images. On the 
other hand, quantitative examination of T1 relaxation 
time showed significant increases in the bilateral means 
of T1 values (ms) in ROIs of the SN compacta and the 
striatum after the present MPTP regimen, relative to the 
pre-MPTP administration data. No significant change 
was observed in T2 relaxation times in any of the ROIs.
The cause of the increase in T1 in the dopaminergic 
neurons in the ROIs remains unclear, but may reflect 
an MPTP-induced decrease in melanin concentration 
in these neural cells. Melanin in normal dopaminergic 
neurons associates with metals to create a ferromagnetic 
field. The MPTP-induced decrease in melanin level may 
increase the T1 value of neurons in the SN.
In contrast to PD model marmosets, iron accumula-
tion in PD patients triggered regional T1 and T2 value 
changes compared to healthy subjects (Vymazal et al., 
1999). However, the implications of increased T1 values 
reported in various studies in PD patients must be viewed 
with caution because T1 values depend on the molecular 
environment and the strength of the magnetic field.
Our MRI data on MPTP-treated marmosets were com-
pared to the results of our earlier in-vivo PET study 
(Ando et al., 2012) using other MPTP-treated marmosets. 
This PET study showed that the binding potential of a 
radioligand tracer ([11C]PE2I) to dopamine transporters 
was decreased in the striatum of MPTP-treated marmo-
sets compared to MPTP-free marmosets. It should be 
emphasized that a BP decrease at the putamen is strongly 
correlated with a decreased level of locomotion (r = 0.98). 
Together with the present MRI study, our data showed 
that in-vivo imaging of marmoset brains is important and 
useful to characterize the MPTP model in terms of its 
utility for preclinical evaluation of medical treatments.
Histology of brain damage
After experiments 1–4 had been completed, only four 
of 10 marmoset brains were examined by immunohis-
tochemical staining with TH antibody. The purpose of 
the histology analysis in the present behavioral study was 
to confirm that brain damage was caused by the present 
MPTP regimen. The histological analysis confirmed 
that the dopaminergic neural system of the striatum was 
clearly and extensively damaged, as has been reported in 
previous studies (Waters et al., 1987; Phillips et al., 2017).
For the brains of marmosets (e.g. CM7) that received the 
present MPTP regimen, detailed histological analysis 
was reported in other MRI studies, wherein decreased 
volumes of tissue in the SN (Hikishima et al., 2015a) and 
a reduction in nigrostriatal fibers between the SN and 
the striatum (Hikishima et al., 2015b) were observed as 
described above.
In addition to the histological results in the present study, 
we found that the decreased TH-stained area in the stri-
atum, calculated using ImageJ software, correlated with 
the decreased level of locomotion (correlation coefficient 
of 0.83) in marmosets (n = 5) that received two regimens 
of MPTP HCl at 2, 2, and 1 mg/kg s.c. on three consec-
utive days, respectively (unpublished study by Nishime 
C, Inoue R, Nishinaka E, and Ando K). Although the 
role of TH staining in the present study was for gross 
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confirmation of neural damage, the present histological 
analysis corroborated that neural damage in the striatum 
was clear by the present MPTP regimen.
Conclusion
Baseline locomotion and some behavioral traits in a com-
mon marmoset PD model with a single MPTP regimen 
were characterized. The results increase our understand-
ing of the utility and limitations of the PD marmoset 
model in preclinical evaluations of medical treatments.
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